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A B S T R A C T   
Background: Prenatal exposure to endocrine-disrupting compounds (EDCs) may contribute to endocrine-related 
diseases and disorders later in life. Nevertheless, data on in utero exposure to these compounds are still scarce. 
Objectives: We investigated a wide range of known and novel nonpolar EDCs in full-term human amniotic fluid 
(AF), a representative matrix of direct fetal exposure. 
Methods: Gas chromatography high-resolution mass spectrometry (GC-HRMS) was used for the targeted and non- 
targeted analysis of chemicals present in nonpolar AF fractions with dioxin-like, (anti-)androgenic, and (anti-) 
estrogenic activity. The contribution of detected EDCs to the observed activity was determined based on their 
relative potencies. The multitude of features detected by non-targeted analysis was tentatively identified through 
spectra matching and data filtering, and further investigated using curated and freely available sources to predict 
endocrine activity. Prioritized suspects were purchased and their presence in AF was chemically and biologically 
confirmed with GC-HRMS and bioassay analysis. 
Results: Targeted analysis revealed 42 known EDCs in AF including dioxins and furans, polybrominated diphenyl 
ethers, pesticides, polychlorinated biphenyls, and polycyclic aromatic hydrocarbons. Only 30% of dioxin activity 
and <1% estrogenic and (anti-)androgenic activity was explained by the detected compounds. Non-targeted 
analysis revealed 14,110 features of which 3,243 matched with library spectra. Our data filtering strategy 
tentatively identified 121 compounds. Further data mining and in silico predictions revealed in total 69 suspected 
EDCs. We selected 14 chemicals for confirmation, of which 12 were biologically active and 9 were chemically 
confirmed in AF, including the plasticizer diphenyl isophthalate and industrial chemical p,p’-ditolylamine. 
Conclusions: This study reveals the presence of a wide variety of nonpolar EDCs in direct fetal environment and 
for the first time identifies novel EDCs in human AF. Further assessment of the source and extent of human fetal 
exposure to these compounds is warranted.   
1. Introduction 
Environmental pollutants are increasingly recognized for their abil-
ity to alter fetal programming during critical windows of development 
(Heindel et al., 2015; Vrijheid et al., 2016). Prenatal exposure to 
endocrine-disrupting compounds (EDCs) is of particular concern, as 
EDCs can interfere with hormonal signalling and affect many develop-
mental processes tightly regulated by hormones (Gore et al., 2015; Ho 
et al., 2016; Vaiserman, 2014). Growing scientific evidence suggests that 
prenatal exposure to EDCs is a contributing factor in the increasing 
prevalence of endocrine-related disorders such as early onset of puberty 
(Lee et al., 2019), hormone-sensitive cancers (Rachoń, 2015), metabolic 
and neurobehavioral disorders and cardiovascular diseases (Bellanger 
et al., 2015; Heindel et al., 2017; Pinson et al., 2016), and that these 
effects might be transgenerational (Heindel and Vandenberg, 2015). The 
EDC mediated developmental programming of adult-onset disease is 
now a public health concern that requires careful scrutiny. Nevertheless, 
the tools for comprehensive evaluation of in utero exposure to EDCs, 
crucial for accurate risk assessment, are still lacking. 
EDCs are chemically very diverse and include compounds with a 
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wide range of physicochemical properties, including differing polarity. 
Nonpolar, lipophilic EDCs are ubiquitously present in the environment 
with a widespread chronic, low-level exposure in the general population 
(Bonefeld-Jørgensen et al., 2014; Lee et al., 2006). Many nonpolar EDCs 
have long elimination half-lives, tend to accumulate over time in the 
maternal body lipids, and can be mobilized during gestation when 
maternal energy expenditure and metabolism change rapidly to support 
the developing fetus (Lehmann et al., 2014). Pollutants eliminated from 
the maternal compartment (e.g., via placental transport to the fetus) 
might, at the same time, be gradually released from maternal lipophilic 
storage depots back into the blood (Barr et al., 2005). The circulating 
low-level of persistent pollutants in the maternal compartment may 
result in chronic exposure to the fetus. Although many factors influence 
transplacental transport of environmental chemicals, in general EDCs 
with higher lipophilicity are thought to more readily cross the placenta 
than the more hydrophilic compounds (Li et al., 2013; Poulsen et al., 
2009). 
Nowadays, there are thousands of chemicals in commercial use that 
pregnant women might be exposed to, with the vast majority lacking 
toxicity data on endocrine endpoints (Andersson et al., 2016; World 
Health Organization, 2013). The majority of research on prenatal 
exposure is focused only on a limited number of well-known environ-
mental pollutants often measured in maternal matrices as a surrogate for 
the fetal environment (Cooke, 2014; Deji et al., 2021; Kahn et al., 2020; 
Marie et al., 2015; Mitro et al., 2015). However, considering complex 
placental and in utero specific toxicokinetics, extrapolation of exposure 
from the maternal to the fetal compartment remains challenging 
(Prouillac and Lecoeur, 2010; Syme et al., 2004). It is, therefore, crucial 
to move from the quantification of a limited number of known EDCs to 
the characterization of complex mixtures, including possible novel and 
biologically active compounds, preferably in in utero specific matrices. 
Amniotic fluid (AF) is a unique complex nutritious milieu and a re-
pository matrix for many environmental xenobiotics that the mother and 
the fetus are exposed to throughout pregnancy. Compounds in AF 
continuously circulate through foetal membranes (through foetal swal-
lowing and excretion) and therefore AF represents not only maternal but 
also fetal toxicokinetics (Underwood et al., 2005). The ongoing cycle of 
fetal ingestion and excretion of AF may result in fetal accumulation (Burt 
et al., 2012; Mann et al., 1996)) and/or prolonged fetal exposure 
(Bradman et al., 2003). Despite the low lipid content of AF (approx. 
0.15 g/L), highly lipophilic compounds, such as polybrominated 
diphenyl ethers (PBDEs) or organochlorines, have been previously 
detected in this matrix, and their presence in AF indisputably demon-
strates placental transfer and fetal exposure (Barmpas et al., 2020; Miller 
et al., 2012). Although, concentrations of xenobiotics detected in AF are 
usually lower than in maternal blood and difficult to detect using con-
ventional methods, advances in analytical chemistry provide sensitive 
methods for qualitative and quantitative detection of these compounds, 
even at trace levels (pg-ng/mL range). Nevertheless, the use of AF for 
assessment of prenatal exposure to nonpolar EDCs is still largely 
unexplored. 
Recently, we developed a robust, non-discriminating method for the 
extraction of EDCs with a wide range of polarities from full-term AF 
(Dusza et al., 2019). We used an effect directed approach (EDA) in which 
chromatographic separation of chemicals in AF extract allowed for 
separation of compounds with different polarities into fractions and 
consequent reduction of the chemical complexity. The endocrine dis-
rupting activity profile of the fractions was determined with a battery of 
cell-based in vitro reporter gene bioassays. This approach revealed sig-
nificant dioxin-like, (anti-)androgenic, and (anti-)estrogenic activity in 
the nonpolar AF fractions, that could not be attributed to the presence of 
endogenous hormones (Dusza et al., 2019). The goal of the current study 
was to identify known and possibly novel EDCs responsible for the 
observed endocrine activity. To this end, we performed targeted and 
non-targeted analysis of EDCs in nonpolar fractions using gas chroma-
tography high resolution mass spectrometry (GC-HRMS). The 
contribution of the known EDCs detected in AF to the activity observed 
in the fraction was determined using relative potency (REP) values. To 
investigate the remaining unexplained activity further, we developed an 
innovative, weight of evidence approach to prioritize novel EDCs from 
the multitude of m/z features identified through the non-targeted 
analysis. This approach takes advantage of curated and freely avail-
able resources to mine data and predict biological properties of un-
known chemicals. We compared the ‘hits’ from the non-targeted GC- 
HRMS analysis to a battery of experimental data obtained from high- 
throughput bioassays (ToxCast and Tox21 databases (Richard et al., 
2016) available through EPA CompTox Chemicals Dashboard (Williams 
et al., 2017)), predictive QSARs (OPERA (Mansouri et al., 2018) and 
Danish (Q)SARs Database (Klimenko et al., 2019)) and endpoint specific 
profiling models (OECD QSAR Toolbox (Schultz et al., 2018)). Unknown 
compounds prioritized based on in silico and in vitro profiling were 
purchased and their presence in the active fraction was chemically and 
biologically confirmed with GC-HRMS and bioassay analysis, 
respectively. 
2. Materials and methods 
2.1. AF sampling, extraction and fractionation 
Approximately, 50 mL of AF was collected during amniotomy at full- 
term vaginal delivery, from four healthy pregnancies, with ethical 
approval and informed consent, and immediately frozen at − 80 ◦C (U.K. 
National Health Service, reference E5431, 2008). Samples were pooled, 
homogenised, and 100 mL was extracted with a combination of solid- 
phase extraction (SPE) and dispersive liquid/liquid extraction (DLLE) 
as described in Dusza et al. (2019). Briefly, aliquots of AF (5 mL) diluted 
with 3 mL deionized water were loaded on the SPE columns (Oasis HLB, 
Waters Corp., Milford, MA), the aqueous eluents were collected for 
further extraction with DLLE, the cartridges were rinsed and the analytes 
eluted with MeOH. The solvent was evaporated with nitrogen, to a final 
volume of 1 mL. DLLE was performed twice, on the aqueous eluents 
acidified with acetate/acetic acid buffer (pH ~4.5), using acetone as 
dispersive solvent and DCM as extraction solvent. The samples were 
vortexed, centrifuged and the organic phases combined and evaporated 
to dryness with nitrogen. The extracts remaining after SPE were trans-
ferred to the residues in the DLLE tubes, vortexed, combined and further 
concentrated to 1 mL. The final extract was centrifuged at 20 800g to 
separate the precipitate formed after sample concentration. The 
extraction procedure was repeated with an AF sample spiked with a mix 
of reference compounds containing 18 EDCs from 10 different classes 
and covering a wide range of hydrophobicity (logP 1.65–7.19). The 
average relative recovery of the analytes was 87 ± 12% RSD, n = 3 (see 
Dusza et al., 2019). 
A total of 150 µL of non-spiked AF extract (representing 100 mL AF) 
was injected on a reversed-phase (RP) Phenomenex Kinetex C18 (100 
mm × 2.1 mm, 5 μm pore size) column and separated into 25 fractions 
using high-performance liquid chromatography (Agilent 1260 HPLC 
system) and a gradient elution using water and MeOH. Each of the 25 
fractions was tested for the (anti-)estrogenic, (anti-)androgenic and 
dioxin-like activity using reporter gene bioassays (Dusza et al., 2019). In 
this study, the nonpolar fractions were further analysed with targeted 
and non-targeted GC-HRMS analysis to screen for the known and un-
known (novel) nonpolar EDCs present in the active fractions. Moreover, 
an extraction blank (i.e., a full extraction procedure performed with a 
non-spiked HPLC grade water) and a solvent blank (i.e., solvents used to 
prepare AF fractions for GC-HRMS analysis) were also included in the 
analysis. A schematic representation of the study design is presented in 
Fig. 1. Details of chemicals, reagents and bioassays used are given in 
Supplementary Material S1.1 and S1.2. 
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2.2. Relative effect potency (REP) 
REP values of the individual compounds were determined by 
dividing the EC50 value obtained for the respective positive control (E2, 
DHT or TCDD) by the EC50 obtained for the test compound. In the AR- 
antagonistic assays, the REP values were calculated as the potency of a 
test compound relative to the EC50 of the positive control, flutamide 
(Flu). The REP values were calculated based on EC50 data derived in this 
study or collected from open literature sources or retrieved from Tox-
Cast/Tox21 (Table S1). The ER/anti-AR/DR activity was transformed 
into estrogenic (EEQs), anti-androgenic (Anti-AR-EQs) and dioxin 
(TEQs) equivalent units, by multiplying the REP values with the con-
centrations of compounds measured quantitatively in the AF fraction. 
The equivalent units were expressed in ng of E2-EQs, Flu-EQs or TCDD- 
EQs per litre AF (ng/L), respectively. 
2.3. GC-HRMS sample preparation 
Prior to GC-HRMS analysis, the methanol fractions were evaporated 
to 50 µL under nitrogen gas using a Thermo Scientific Reacti-Therm 
(Waltham, MA 02541). The 50 µL sample and two 30 µL dichloro-
methane rinses were transferred to an amber GC vial with a 350 µL fused 
glass insert. Each sample was spiked with 10 µL of internal standard 
solution to achieve a final concentration of phenanthrene-d10 and 
chrysene-d12 of 20 ng/mL and a concentration of each compound in the 
carbon number distribution marker of 93 ng/mL. The final volume of 
each sample was brought to 150 µL with dichloromethane. The 
deuterated internal standards were used to verify injection consistency 
and column performance, while the carbon number distribution marker 
was used for non-targeted HRMS analysis as discussed below. Overall, 
the injection consistency during GC-HRMS analysis was high, with the 
coefficient of variation (CV) for both internal standards of <5% (Sup-
plementary Excel File). The two columns used showed a high level of 
reproducibility with CV for RT drift for both internal standards of less 
than 0.1%. 
2.4. GC-HRMS data collection and targeted analysis 
Sample extracts were analyzed using a Thermo GC-Orbitrap mass 
spectrometer, which was equipped with a Thermo Trace 1300 GC and 
TriPlus RSH autosampler operated in positive electron ionization (EI) 
mode. Helium (99.9999% purity) and nitrogen (99.999% purity) were 
used as the carrier and c-trap gases, respectively. Two GC runs were 
performed; the first run was used to quantify dioxins, furans, and pol-
ybrominated diphenyl ethers (PBDEs) separated on a 15-m Restek Rtx- 
5SilMS column (0.25 mm inner diameter × 0.25 µm film thickness), 
while the second run was used to quantify polychlorinated biphenyls 
(PCBs), pesticides, and non-brominated flame retardants and for non- 
targeted HRMS analysis separated on a 30-m Restek Rtx-5Sil MS col-
umn (0.25 mm inner diameter × 0.25 µm film thickness). For the full list 
of compounds see Supplementary Material, Table S2. For targeted 
analysis of dioxins, furans, and PBDEs, 6 µL of the extract was injected 
into a programmable temperature vaporizer inlet (PTV) operating in 
large volume injection (LVI) mode. The PTV-LVI injection occurred in 
Fig. 1. Study design for identification of nonpolar endocrine disruptors (EDCs) in full-term amniotic fluid (AF), using a combination of targeted and non-targeted 
chemical analysis, reporter gene bioassays, toxicity profiling and prediction tools. 
H.M. Dusza et al.                                                                                                                                                                                                                               
Environment International 158 (2022) 106904
4
the following stages: (1) injection: split mode for 0.05 min at 45 ◦C with 
a split gas flow rate of 100 mL/min, (2) evaporation: split mode for 1 
min with a split flow of 250 mL/min while the temperature increased at 
14.5 ◦C/s to 60 ◦C, (3) transfer: splitless mode for 2 min and increased to 
330 ◦C at 14.5 ◦C/s, (4) cleaning: split mode for 5 min with a split flow of 
100 mL/min and the temperature increased 14.5 ◦C/s to 350 ◦C, and (5) 
post-cycle: split mode and the temperature was maintained at 350 ◦C for 
the remainder of the GC run. The carrier gas flow rate was 1.5 mL/min. 
The oven temperature ramp was: 75 ◦C for 0.4 min, 200 ◦C at 30 ◦C/min, 
260 ◦C at 10 ◦C/min with a 3 min hold, 310 ◦C at 5 ◦C/min, and to 
360 ◦C at 50 ◦C/min with a 3 min hold. The transfer line and source were 
maintained at 300 ◦C. Data were collected between 5.3 and 23 min (the 
total run time was 34 min) in full-scan mode with 60,000 resolution and 
a scan range of 220 to 850 m/z. The instrument was calibrated before 
sample analysis to <1 ppm mass accuracy. 
Sample extracts were injected a second time to evaluate the con-
centration of PCBs, pesticides, and non-brominated flame retardants and 
for non-targeted analysis. A 3-µl sample was injected into a 290 ◦C 
splitless inlet operated in splitless mode. The carrier gas flow rate was 1 
mL/min. The transfer line and the source temperature were maintained 
at 300 ◦C. The oven temperature ramp was as follows: 50 ◦C hold for 0.5 
min, 221 ◦C at 7 ◦C/min and held for 2 min, 222 ◦C at 0.1 ◦C/min, and 
320 ◦C at 7 ◦C/min and hold for 3 min (total run time of 49 min). Data 
were collected in full-scan mode between 5 and 45 min with a scan range 
of 50 to 750 m/z. 
The extracted ion chromatogram (XIC) was used for quantification 
using the most abundant peak in the mass spectrum for each compound. 
Compound identity was confirmed using retention time and two con-
firming ions (Supplementary Material, Table S2). Quantification was 
performed by an external eight-point calibration curve prepared by se-
rial dilutions of the calibration standards (0.005 to 15 ng/mL). LOD for 
each compound was determined by injecting 7 low-calibration stan-
dards near the detection limits (between 0.05 and 2 ppb, depending on 
the concentration of the analyte in the standards purchased from 
Accustandard) and was calculated as t (the student’s t value for a 99% 
confidence level with n-1 degrees freedom, t = 3.14) times standard 
deviation divided by the calibration curve slope (Long and Winefordner, 
1983). The concentration of compound detected in AF fractions above 
LOD was corrected for the preconcentration factor and reported in ng/L 
AF, ng/g lipids (based on the average AF lipid content at full term (0.15 
g/L) as reported in the literature (Biezenski et al., 1968; Singh and 
Zuspan, 1973)) and as a non-lipid adjusted molar concentration (M). 
2.5. Non-targeted GC-HRMS data analysis 
The data files produced by the GC-HRMS runs on the 30-m column 
were re-processed for non-targeted analysis using Thermo TraceFinder 
software (EFS Version 4.1 SP 1) with the Deconvolution Plugin. The 
Deconvolution Plugin was used to automate forward mass spectra 
searching to the 2017 NIST Mass Spectra Library (NIST/EPA/NIH EI and 
NIST Tandem Mass Spectral Library Version 2.3) and a high-resolution 
library developed using certified standards. The NIST library contains 
over 250,000 compounds while the in-house library contains 300 
compounds. Features were integrated for a signal to noise (S/N) ratio of 
>10, a minimum total ion chromatogram (TIC) intensity of 1,000, and a 
99% allowable ion overlap window. The compounds in the carbon 
number distribution marker were used to align peaks and to calculate 
the retention index (RI) of each m/z feature. The RI of each peak was 
compared to the library match RI data contained in the spectral libraries. 
The allowable RI delta was 300. The library search was performed with a 
reverse match factor (RSI/Rev) score threshold of 500 (a comparison 
score of the obtained spectrum to the library spectrum). The compound 
with the highest RSI score was assigned as the identification. A data 
filtering strategy (Supplementary Material S1.3) based on a calibration 
standard containing 350 compounds (Supplementary Excel File), was 
performed using MATLAB (vR2018a). Briefly, the script exported the 
identified features for all samples to the PubChem database to retrieve 
International Chemical Identifiers (InChi) and CAS numbers, and 
compared features to a single standard containing the 350 compounds. 
When a feature was present in the calibration standard list and in the 
sample it was flagged as Identified Known, when a feature was present in 
the sample but not in the calibration standard, it was flagged as Iden-
tified Unknown. The unmatched features were not included in this 
analysis. Features detected only in the solvent blank, extraction blank, 
and calibration standard (not detected in any of the samples) were also 
not included in the analysis. The selected Identified Knowns were 
further quantified using a full calibration curve. 
2.6. Identification of candidate EDCs 
The peak intensities of the Identified Unknowns found in the AF 
fractions were visualized with colour-coded heatmap using ClustVis web 
tool (Metsalu and Vilo, 2015). Identified Unknowns that correlated with 
the active fractions were chosen for further analysis when the following 
criteria were met: a) not present in the extraction/solvent blank or peak 
intensity at least 5 × higher than in the extraction/solvent blank; b) RSI/ 
Rev Dot product > 700; c) log P value (octanol–water partition coeffi-
cient), experimental or predicted > 4.0. Experimental Log P values were 
retrieved from Chemspider (http://www.chemspider.com/), PubChem 
(https://pubchem.ncbi.nlm.nih.gov/) database or publicly available 
Episuite Kowwin v1.67, U.S. EPA software (available at www.epa.gov). 
Predicted values were estimated with Episuite Kowwin v1.67 and 
OPERA software (OPEn structure–activity/property Relationship App) 
(Mansouri et al., 2018). Identified Unknowns that met the above criteria 
were further evaluated for their potential (anti-)estrogenic/androgenic/ 
dioxin-like activity using a combination of publicly available experi-
mental data and predictive models. 
2.6.1. Experimental data 
Experimental data were retrieved from ToxCast and Tox21 high- 
throughput bioassays (Richard et al., 2016) that measured agonistic 
and antagonistic activity directly linked to estrogen receptor (ER), 
androgen receptor (AR) and aryl hydrocarbon receptor (AhR) activation 
or binding using the U.S. Environmental Protection Agency’s (EPA) web- 
based CompTox Chemicals Dashboard platform (https://comptox.epa. 
gov/dashboard, Williams et al., 2017). InChi identifiers of the Identi-
fied Unknowns were used as an input format. Compounds were 
screened, using a batch search mode, against a total of 31 bioassays (2 
AhR, 12 AR and 17 ER assays), comprised of various reporter gene and 
binding assays. Where possible, for each antagonistic assay comple-
mentary viability assays were included to ensure that the observed 
antagonistic activity was not caused by cell death. For a detailed list of 
bioassays used see Table S3. Additionally, Identified Unknowns were 
checked against experimental database available through QSAR Toolbox 
application (OECD QSAR Toolbox, https://www.qsartoolbox.org), 
which included data on three receptor-mediated endpoints i.e., 
androgen binding affinity (ARBA) for 1099 compounds, estrogen rela-
tive binding affinity (ERBA) for 3715 compounds, and AhR activity for 
142 compounds. Identified Unknowns were also checked against a high 
throughput screening database for the activation of AhR, developed by 
The Scripps Research Institute Molecular Screening Center (available 
online at https://pubchem.ncbi.nlm.nih.gov/bioassay/2796,) and 
against Human Metabolome Database (Wishart et al., 2018), to screen 
for known endogenous compounds. 
2.6.2. Profiling and QSARs 
Quantitative-Structure Activity Relationship (QSAR) models were 
used as a part of the weight of evidence to fill data gaps where experi-
mental data were scarce and to further predict chemicals with potential 
(anti-)estrogenic/androgenic/dioxin activity. InChI strings of the Iden-
tified Unknowns were converted to a simplified molecular-input line- 
entry system (SMILES) with OpenBabel software (O’Boyle et al., 2011), 
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accessed through http://www.cheminfo.org/. SMILES structure de-
scriptors, were used as input for QSARs. Two separate QSAR tools were 
used. First, OPERA (OPEn structure–activity/property Relationship 
App) a command-line application with two QSAR models i.e., CoMPARA 
(Collaborative Modelling Project for Androgen Receptor Activity) 
(Mansouri et al., 2020) and CERAPP (Collaborative Estrogen Receptor 
Activity Prediction Project) (Mansouri et al., 2016). Second, an online- 
based Danish QSAR Database with estimates from>200 free and 
commercially available (Q)SAR platforms (Danish (Q)SAR Database, 
Division of Diet, Disease Prevention and Toxicology and Food Institute, 
Technical University of Denmark 2015, http://qsar.food.dtu.dk/). Here, 
a battery of modelling systems was used to predict ER activation and 
binding, AR antagonism and AhR activation (Klimenko et al., 2019). 
Moreover, ER binding profiler available through QSAR Toolbox was 
additionally used (https://www.qsartoolbox.org). The profiler predicts 
chemical binding to ER based on molecular weight (MW) and structural 
characteristics, classifying chemicals as very strong, strong, moderate, 
weak or non-binders. A detailed description of each QSAR and profiling 
tool is given in Table S4 and Fig. S1. Identified Unknowns were ranked 
based on the weight of evidence for their possible endocrine-disrupting 
potency (the experimental, profiling and QSAR data was given the same 
weight) and correlation between the elution profile and the activity 
observed in the fractions (checked manually for each suspected EDC). 
2.7. Chemical and biological confirmation 
Where possible, reference standards for the selected candidate EDCs 
were purchased at the highest commercially available purity (see Sup-
plementary Material S1.1), and their presence in the AF fraction(s) were 
further confirmed with GC-HRMS by comparing their exact masses (5 
ppm mass accuracy tolerance), mass spectra and retention times (RT 
difference of ±0.05 min) to the data obtained during the non-targeted 
analysis. The (anti-)estrogenic/androgenic/dioxin-like activity of the 
selected candidates was further confirmed in the respective bioassays. A 
concentration range of the candidate EDCs (0.01 to 100 µM) was pre-
pared by serial dilution in DMSO and, where needed, was adjusted to 
include more points in the linear part of the concentration–response 
curve. Candidate EDCs were tested with the same media composition 
and final DMSO concentration as used to test AF fractions. 
3. Results 
3.1. Endocrine activity in nonpolar AF fractions 
In the previous study by Dusza et al. (2019), extraction and frac-
tionation of full-term AF into 25 fractions resulted in elevated (anti)-AR 
and DR activity in nonpolar fractions F17-F25. In this study, ER activity 
was tested at the same fraction dilution in which we observed (anti)-AR 
and DR activity, i.e. 2 times dilution. ER activity was observed in all 
except two (F19 and F22) nonpolar fractions tested (Fig. 2A). The 
highest ER activity was observed in F23 and reached 28% of the activity 
of positive control E2, the most potent ER agonist. As shown in our 
previous study (Dusza et al., 2019), elevated DR activation was observed 
in 6 (F17 and F19-23) out of the 9 nonpolar fractions tested, with the 
highest observed activity (F21) reaching 30% of the activity of TCDD, 
the most potent AhR agonist (Fig. 2A). AR activity was present only in 
F21 and F23, with 8% and 20% induction of luciferase activity as 
compared to the highest activity observed for the positive control DHT, 
respectively (Fig. 2A). None of the nonpolar fractions showed anti-ER or 
anti-DR activity. However, anti-AR activity was observed, with 4 frac-
tions (F17-F20, Fig. 2B) showing up to 18% decrease of DHT induced 
luminescence. Based on their activity profile, seven nonpolar fractions 
(F17-F23) were chosen for further targeted and non-targeted chemical 
analysis. 
3.2. GC-HRMS targeted analysis 
A total of 48 known environmental pollutants were measured with 
targeted GC-HRMS analysis of the active nonpolar AF fractions 
(Table S2). Fractions were additionally screened for the presence of 
environmental pollutants by comparing features present in the sample to 
a single standard point in the calibration standard containing 350 
environmental chemicals (Supplementary Excel File), using the data 
filtering strategy (Supplementary Material S1.3). Here, 73 compounds 
were detected as Identified Knowns. From these, 62 were present in 
ToxCast/Tox21database, but only 14 showed endocrine activity in one 
or more high-throughput in vitro screening (HTS) bioassays (Table S3) 
and therefore were additionally quantified with a full calibration curve. 
Compounds from the quantitative, targeted analysis of nonpolar AF 
fractions are presented in Table 1. Moreover, 5 additional nonpolar 
compounds previously detected in the nonpolar AF fractions reported in 
Dusza et al. (2019), were also included in Table 1. In total, 42 com-
pounds were detected above LODs (Tables 1 and S2), including 4 dioxins 
and furans, 10 PBDEs, 12 pesticides, fungicides and herbicides, 6 PCBs, 
and 10 other compounds, such as plasticizers and polycyclic aromatic 
hydrocarbons (PAHs). The concentrations of most compounds were in 
the ng/L range, with the highest concentration detected for o,p’-DDD, 
δ-HCH and p,p’-DDD at 537.2, 498.1 and 274.8 ng/L AF, respectively. 
The lipid adjusted concentrations, based on the AF lipid content of 0.15 
g/L were, as follows, 6.6 times higher than the non-adjusted values 
(Table 1). Eight compounds were detected in the extraction blank above 
the LODs, namely phenol, 2,4,5-trichloro-, PCB 114, TPP, EDP, B[a]P, B 
[b]F, mesitylene and azobenzene (Table 1 and Table S2). For all, except 
Fig. 2. Agonistic (A) and antagonistic (B) activity of nonpolar fractions of 
amniotic fluid (AF) in ER (black), AR (grey), and DR (striped) responsive cell 
lines. Agonistic response is expressed relative to the maximum induction 
observed in the concentration–response curve of the positive control E2 (50 
pM), DHT (0.5 nM) and TCDD (1 nM). Antagonistic activity is measured as a 
decrease in luminescence after co-exposure with 4, 150, and 30 pM of E2, DHT, 
and TCDD, respectively. Results presented as average % of response of 
respective positive control ± SD (n = 3). 
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Table 1 
Environmental pollutants in nonpolar fractions of full-term amniotic fluid (AF) measured with targeted GC-HRMS analysis, including molecular weight (MW), 
partition coefficient (logP), total concentration measured in fractions (expressed in ng/L AF, ng/g lipid and non-lipid adjusted molar (M) concentration), and fraction 
(s) in which compound was detected above the limits of detection (LOD).  
Chemical group Compound name MW LogP^ Conc. (ng/L AF) Conc. (ng/g lipid) Conc. (M) Fraction nr. 
Dioxins and Furans 2,3,7,8-TCDF 306.0 6.53 <LOD <LOD <LOD – 
2,3,7,8-TCDD 322.0 6.80 1.4 9.3 4.6 x10− 12 23 
1,2,3,7,8-PCDF 340.4 6.79 <LOD <LOD <LOD – 
1,2,3,7,8-PCDD 356.4 6.64 0.9 6.0 2.5 × 10− 12 19–20 
1,2,3,4,7,8-HCDF 374.9 NA 4.5 30.0 1.2 × 10− 11 21–22 
1,2,3,4,7,8-HCDD 390.9 7.80 <LOD <LOD <LOD – 
1,2,3,4,6,7,8-HCDF 409.3 7.92 <LOD <LOD <LOD – 
1,2,3,4,6,7,8-HCDD 425.3 8.20 <LOD <LOD <LOD – 
OCDF 443.7 8.60 1.9 12.7 4.3 × 10− 12 17 
OCDD 459.7 8.20 <LOD <LOD <LOD – 
Polybrominated Diphenyl Ethers (PBDEs) BDE 3* 249.1 NA 129.6 864.0 5.2 × 10− 10 21–22 
BDE 28 406.9 5.94a 32.4 216.0 8.0 × 10− 11 17–20 
BDE 47 485.8 6.81a 1.0 6.7 2.0 × 10− 12 21–22 
BDE 99 564.7 6.84 1.1 7.3 1.9 × 10− 12 22 
BDE 100 564.7 7.24a 15.1 100.7 2.7 × 10− 11 20 
BDE 153 643.6 7.90a 7.0 46.7 1.1 × 10− 11 17–18 
BDE 154 643.6 7.82a <LOD <LOD <LOD – 
BDE 180 722.5 NA <LOD <LOD <LOD – 
BDE 183 722.5 8.27a 1.8 12.0 2.5 × 10− 12 20 
BDE 209 959.2 9.97b 34.3 228.7 4.7 × 10− 11 22–23 
6-OH-BDE 47e 501.8 NA 13.7 91.3 2.7 × 10− 11 19–20 
3-OH-BDE 157e 659.6 NA 9.5 63.3 1.4 × 10− 11 19–20 
Pesticides, Fungicides, and Herbicides p,p’-DDT 354.5 6.91 0.8 5.3 2.2 × 10− 12 17 
o,p’-DDT 354.5 6.79c 7.8 52.0 2.2 × 10− 11 19–22 
p,p’-DDE 318.0 6.51 <LOD <LOD <LOD – 
o,p’-DDE 318.0 6.00d <LOD <LOD <LOD – 
p,p’-DDD 320.0 6.02 274.8 1832.0 6.6 × 10− 10 17–22 
o,p’-DDD 320.0 5.87d 537.2 3581.3 1.7 × 10− 9 17–22 
Mirex 545.5 6.89 <LOD <LOD <LOD – 
Endrin 380.9 5.20 51.3 342.0 1.3 × 10− 10 21–22 
Fonofos* 246.3 3.94 1.5 10.0 6.0 × 10− 12 17 
Heptachlor 373.3 6.10 1.0 6.7 2.8 × 10− 12 20 
γ-HCH 290.8 3.72 2.5 16.7 8.6 × 10− 12 22 
α-HCH 290.8 3.80 <LOD <LOD <LOD – 
β-HCH 290.8 3.78 8.6 57.3 2.9 × 10− 11 17–22 
δ-HCH 290.8 4.14 498.1 3320.7 1.7 × 10− 9 17–20 
Triclosane 289.5 4.76 45.7 304.7 1.5 × 10− 10 17–18 
cis-Chlordane 409.8 6.10 <LOD <LOD <LOD – 
trans-Chlordane 409.8 6.22 <LOD <LOD <LOD – 
trans-Nonachlor 444.2 6.35 <LOD <LOD <LOD – 
Hexachlorobenzene 284.8 5.73 <LOD <LOD <LOD – 
Phenol, 2,4,5-trichloro-* 197.4 3.72 27.3 182.0 1.4 × 10− 10 17–23 
Chemical group Compound name MW LogP^ Conc. (ng/L AF) Conc. (ng/g lipid) Conc. (M) Fraction nr. 
Polychlorinated biphenyls (PCBs) PCB 18* 257.5 5.48 0.7 4.7 2.7 × 10− 12 22 
PCB 65 292.0 NA <LOD <LOD <LOD – 
PCB 81* 292.0 NA <LOD <LOD <LOD – 
PCB 105* 326.4 6.79 0.1 0.7 3.1 × 10− 13 21–22 
PCB 114* 326.4 NA 3.5 23.3 1.1 × 10− 11 22–23 
PCB 118 326.4 7.12 <LOD <LOD <LOD – 
PCB 126 326.4 NA <LOD <LOD <LOD – 
PCB 138* 360.9 7.44 1.4 9.3 3.9 × 10− 12 20–22 
PCB 153 360.9 7.75 <LOD <LOD <LOD – 
PCB 166 360.9 7.31 <LOD <LOD <LOD – 
PCB 169 360.9 7.41 <LOD <LOD <LOD – 
PCB 180 395.3 7.72a <LOD <LOD <LOD – 
PCB 206 464.2 9.14 1.6 10.7 3.5 × 10− 12 21 
OH-PCB 61e 308.0 NA <LOD <LOD <LOD – 
Other TPP 326.3 4.59 36.8 245.3 1.1 × 10− 10 21 
EDP 362.4 5.73 2.5 16.7 6.9 × 10− 12 23 
IPyr* 276.3 6.58 1.1 7.3 3.9 × 10− 12 22 
B(a)P 252.3 6.13 69.3 462.0 2.7 × 10− 10 18–22 
B(b)F* 252.3 5.78 3.7 24.7 1.5 × 10− 11 17–23 
DNOP* 390.6 8.10 4.4 29.3 1.1 × 10− 11 18–23 
Pyrene 202.3 4.88 7.5 50.0 3.7 × 10− 11 17–20 
Fluorene* 166.2 4.18 5.7 38.0 3.4 × 10− 11 19–23 
Mesitylene* 120.2 3.42 69.3 462.0 2.7 × 10− 10 17–23 
Azobenzene* 182.2 3.82 251.1 1674.0 1.4 × 10− 9 17–22 
4-Octylphenole 206.3 5.30 <LOD <LOD <LOD – 
Note: compounds were analysed in one pooled AF samples, n = 1; NA - not available; * - targeted analysis of compounds selected from the analysis of 350 envi-
ronmental chemicals; underscore – compounds present in the extraction blank above LOD; ^ - experimental Log P values based on octanol/water partition coefficient 
were retrieved from PubChem or literature; a - Braekevelt et al., 2003; b - Watanabe and Tatsukawa, 1990; c - Swann et al., 1981; d - Howard and Meylan, 1997; e - 
Dusza et al. 2019. 
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phenol, 2,4,5-trichloro- and azobenzene, the concentrations found were 
close to LOD levels (Table S2). 
3.3. DR, (anti-)AR and (anti-)ER activity of detected compounds 
Dioxin-like activity was found for 13 compounds with EC50 values 
ranging from 9.5 × 10− 12 M for the most potent compounds (2,3,7,8- 
TCDD and 1,2,3,7,8-PCDD) to > 1.5 × 10− 5 M for the least potent 
compound (BDE 99) (Table 2). In terms of androgenic activity, only one 
compound (mesitylene) was a weak AR agonist, with EC50 of 6.4 × 10− 5 
M, whereas 23 compounds were AR antagonists. The majority of AR 
antagonists had low to moderate anti-AR potency while two, namely 
BDE 100 (0.1 µM) and p,p’-DDD (0.7 µM), were highly potent (Table 2). 
Estrogenic potency was found for 15 compounds, with EC50 values 
ranging from 2.0 × 10− 6 M (o,p’-DDT) to > 1.5 × 10− 5 M (BDE 28). 
Additionally, 9 compounds were ER antagonists, from which 2,3,7,8- 
TCDD, IPyr, B(b)F and 6-OH-BDE 47 were reported as highly potent 
with IC50 values of 1.0 × 10− 8 M, 3.0 × 10− 7 M, 4.0 × 10− 7 M and 5.0 ×
10− 7 M, respectively (Table 2). 
3.4. Contribution of compounds to the observed bioassay activity 
Total analytical TEQs of the detected DR agonists corresponded to 
3.0 ng TCDD-EQs/L AF (Table 3). Three compounds, namely 2,3,7,8- 
TCDD, 1,2,3,4,7,8-HCDF, 1,2,3,7,8-PCDD, contributed 47%, 17% and 
35% to the estimated total analytical TEQ, respectively (Table 3). Total 
bioassay TEQ of the active nonpolar AF fractions corresponded to 10.0 
ng TCDD-EQs/L AF, from which approximately 30% could be explained 
by the total analytical TEQ (Table 4). Approximately 40% and 48% of 
the bioassay activity observed in F19 and F20 respectively was 
explained by the dioxin-like compounds measured in these fractions, 
whereas the activity observed in F23 could be explained almost entirely 
(97%) by the respective analytical TEQ. For the most DR-active AF 
fraction (F21, Fig. 2A), only 8% of the activity observed was explained 
by the dioxin-like compounds measured in this fraction. Three DR-active 
compounds, namely PCB 114, B[a]P and B[b]F were also detected in the 
extraction blank (Table S2), nevertheless, their levels in the extraction 
blank were low (close to LODs) and thus their contribution to the 
observed activity in the AF fraction was minimal (<1%, Table 3). 
The androgenic activity observed in the F21 and F23 fractions was 
not explained by any of the compounds measured in this study, and the 
contribution of the only weak AR agonist, mesitylene (Tables 1 & 2), to 
the observed AR-activity was negligible. The total analytical Anti-AR- 
EQs measured in the nonpolar AF fractions corresponded to 673.3 ng 
Flu-EQs/L AF (Table 5). The individual chemicals o,p’-DDD, BDE 100 
and p,p’-DDD contributed 48%, 30% and 11%, respectively to the total 
analytical Anti-AR-EQ. The total bioassay Anti-AR-EQ corresponded to 
336.1 µg Flu-EQs/L AF, from which <1% could be explained by the total 
analytical Anti-AR-EQ (Table 6). The ER potencies of the detected 
compounds were much lower than that of the positive control E2, with 
the REP values between 6 and 8 orders of magnitude below E2. Conse-
quently, the calculated total analytical EEQ was low and corresponded 
to 0.4 pg E2-EQs/L AF (Table 7). o,p’-DDD contributed 59% to the total 
analytical EEQ, followed by triclosan (15%) and p,p’-DDD (7%). The 
total bioassay EEQ corresponded to 1.8 ng E2-EQs/L from which < 1% 
could be explained by the total analytical EEQ (Table 8). The anti-ER 
activity was not observed in any of the fractions tested (Fig. 2B). 
3.5. Non-targeted GC-HRMS analysis: Filtering and screening of the 
Identified Unknowns 
A total of 14,110 features were found in all the fractions, including 
solvent and extraction blanks, from which 3,243 were match identified 
with NIST/in house database. After applying the data filtering strategy 
(see Supplementary Material S1.3) the resulting chemical list contained 
977 unique compounds: 73 Identified Knowns, 904 Identified 
Table 2 
Compounds detected in nonpolar fractions of amniotic fluid by targeted GC- 
HRMS analysis and their dioxin-like (DR), androgenic (AR), anti-androgenic 
(anti-AR), estrogenic (ER) and anti-estrogenic (anti-ER) potencies measured as 
half maximal effect (EC50) or inhibition (IC50) concentration, as reported in in 
vitro reporter gene bioassays.   



















– – – 1.0 ×











NA NA NA NA 21–22 
OCDF 4.0 ×
10− 8b 
NA NA NA NA 17 
BDE 3 – – 5.9 ×


















– – 22 









– – 17–18 




















NA NA NA NA NA 19–20 

























Fonofos – – 2.9 ×
10− 5^ 
– – 17 
Heptachlor – – – – – 20 
γ-HCH – – 4.0 ×
10− 6d 
NA – 22 
β-HCH – – – 2.8 ×
10− 6^ 
– 17–22 
δ-HCH NA – 5.1 ×
10− 5^ 
NA – 17–20 















PCB 18 NA NA NA NA NA 17–22 
PCB 105 4.0 ×
10− 7b 
NA NA NA NA 21–22 
PCB 114 4.0 ×
10− 7b 
NA NA NA NA 22–23 





PCB 206 NA NA NA NA NA 21 





EDP – – – – – 23 
Pyrene – – 2.5 ×
10− 6^ 
– – 17–20 
Fluorene – – – – – 19–23 
(continued on next page) 
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Unknowns. The remaining 2,428 compounds fell into the Ambient 
Background Noise and were eliminated because these features were 
likely solvent or sample preparation artefacts. 
The strategy for filtering and prioritization of Identified Unknowns is 
shown in Fig. S1. The heatmap (Fig. S1), showing relative peak in-
tensities of the Identified Unknowns (calculated as z scores), was 
generated for a visual inspection of the chemical complexity of each 
fraction and corroboration of the correlation between compound elution 
and bioassay activity. Only compounds with RSI/Rev Dot Product Score 
above 700 were included in the generation of the heatmap and further 
analysis. This threshold was based on the observed RSI/Rev of the 
Identified Knowns, which for the majority of compounds fell between 
700 and 999. Further, the lipophilicity of compounds was used to filter 
chemicals based on the correlation between their predicted logP 
(Kowwin and OPERA) and their elution profile. Based on the elution 
profile of the reference compounds (logP ≥ 4.0 observed in ≥ F17, Dusza 
et al., 2019), only compounds with logP ≥ 4.0 were included in the 
subsequent analysis. For the 67 targeted compounds, a high correlation 
was found between experimental and predicted logP values estimated 
with both Kowwin (r = 0.95) and OPERA (r = 0.92) software (Fig. S2). 
For a few compounds, such as BDE 209 and B(b)F, Kowwin over-
estimated, whereas OPERA underestimated the logP values (Fig. S2). To 
Table 2 (continued )  















Mesitylene – 6.4 ×
10− 5 
– – – 17–23 


























DNOP – – – – – 23 
Note: NA, not available; ^, partial agonist/antagonist i.e., maximum activity 
below 100% of the activity of the positive control; a, own data; b, based on TEF 
values (WHO, 2005); c, Hamers et al., 2006; d, Misaki et al., 2015; e, Aït-Aïssa 
et al., 2010; f, Hamers et al., 2011; g, Vondráček et al., 2017; h, Legler et al., 
1999; all other data were retrieved from ToxCast bioassays: TOX21_-
AhR_LUC_Agonist, TOX21_AR_LUC_MDAKB2_Agonist TOX21_ER-
A_LUC_VM7_Agonist, TOX21_ERA_LUC_VM7_Antagonist_0.1nM_E2. Details of 
each bioassay used are given in Supplementary Material Table S1. 
Table 3 
Analytical Toxic Equivalents (TEQs) of individual chemicals based on GC-HRMS analysis of the nonpolar fractions of the full-term amniotic fluid (AF), expressed in ng 
TCDD equivalents/L AF (ng TCDD-EQs/L).    








REPs* F17 F18 F19 F20 F21 F22 F23 
2,3,7,8-TCDD 1.0 – – – – – – 1.4 1.4 47 
1,2,3,7,8-PCDD 1.0 – – 0.3 0.7 – – – 1.0 35 
1,2,3,4,7,8- 
HCDF 
0.1 – – – – 0.3 0.2 – 0.5 17 
OCDF 3 ×
10− 4 
6 × 10− 4 – – – – – – 6 × 10− 4 <1 
BDE 99 1 ×
10− 6 
– – – – – 1 ×
10− 6 
– 1 × 10− 6 <1 
BDE 153 1 ×
10− 5 
1 × 10− 4 3 × 10− 6 – – – – – 1 × 10− 4 <1 
BDE 183 4 ×
10− 6 
– – – 8 ×
10− 6 
– – – 8 × 10− 6 <1 
6-OH-BDE 47 7 ×
10− 6 
– – 9 ×
10− 5 
– – – – 9 × 10− 5 <1 
PCB 105 3 ×
10− 5 




– 3 × 10− 6 <1 
PCB 114 3 ×
10− 5 




1 × 10− 4 <1 
B[a]P 2 ×
10− 5 








– 1 × 10− 3 <1 
B[b]F 6 ×
10− 3 










2 × 10− 2 1 




0.3 0.7 0.3 0.2 1.4 3.0 100 
Note: *, relative potency (REP) values were based on our own data or data retrieved from the literature as indicated in Table 2 and Supplementary Material Table S1. 
Table 4 
Toxic Equivalents (TEQs) based on the reporter gene activity (bioassay TEQs) and GC-HRMS analysis (analytical TEQs) of the nonpolar fractions of full-term amniotic 
fluid (AF) expressed in ng TCDD equivalents/L AF (ng TCDD-EQs/L).  
Fraction number Bioassay TEQs (ng TCDD-EQs/L)* Analytical TEQs (ng TCDD-EQs/L) Explained (%) 
F17  1.0 4 × 10− 3 <1 
F18  – 4 × 10− 4 – 
F19  0.8 0.3 40 
F20  1.5 0.7 48 
F21  3.3 0.3 8 
F22  2.0 0.3 13 
F23  1.5 1.4 97 
∑  10.0 3.0 30 
Note: *, agonistic activity of AF fractions was measured with DR-GFP reporter gene assay as described in the method section. 
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ensure that no compound was eliminated from further analysis based on 
an inaccurate logP prediction, both tools were used to predict logP 
values of the Identified Unknowns, and any inconsistencies in the pre-
dictions were checked against online data sources (e.g., PubChem). In 
general, a good correlation (r = 0.725) was found between the logP from 
the two prediction tools nevertheless, after the discrepancy check, 27 
additional compounds were included in further analysis. 
The final list of Identified Unknowns consisted of 121 unique com-
pounds (Supplementary Excel File), of which squalene and heptadecane 
were the only endogenous metabolites. These compounds were further 
evaluated for their endocrine activity using experimental data available 
through various ToxCast and Tox21 HTS bioassays (CompTox Chemicals 
Dashboard, Table S3), and ERBA and ARBA experimental databases 
(OECD QSAR Toolbox). Of the 121 compounds, 47 were found on the 
CompTox Chemicals Dashboard, of which only 7 were tested for their 
endocrine activity in ToxCast/Tox21 HTS bioassays. From the 7 com-
pounds, 4 were weak ER agonists (EC50 > 1 µM) and one compound, 
allethrin, was both a weak ER and AR antagonist (EC50 6–7 × 10− 5 µM, 
Table S5). Additionally, five compounds were also tested in ERBA and 
ARBA of which 4 were inactive and one, benzoin isobutyl ether, was 
weakly active in both assays (Table S5). There were no Identified Un-
knowns that matched PubChem or OECD QSAR Toolbox experimental 
databases for activation of the AhR. Compounds were further estimated 
for their biological activity using various QSARs and profiling tools with 
endocrine endpoints (Table S4). Here, 69 compounds were found active 
in one or more QSARs (Supplementary Excel File). Compounds were 
further prioritized based on commercial availability. The resulting 14 
compounds listed in Table 9 were purchased, and chemically and bio-
logically confirmed with GC-HRMS and reporter gene bioassay analysis, 
respectively. 
3.6. Chemical and biological confirmation of candidates 
The 14 prioritized candidates were tested for both agonistic and 
antagonistic potency (Fig. 3). Nine compounds showed anti-androgenic 
activity, with IC50 values ranging from 1.4 × 10− 5 M (CAB) to 5.2 ×
10− 6 (BMD). For all but one compound (BFBT), full antagonism was 
observed (Table 9). In general, tested candidates were 5- to 37-fold less 
potent than the reference antiandrogen flutamide. Additionally, four 
compounds i.e., BMD, NABD, BFPT, and allethrin, exhibited cytotoxicity 
in the concentration range tested (Fig. S3). No compounds showed 
androgenic activity, except for diphenyl isophthalate, which was AR 
active, but only when co-exposed with the positive control DHT, 
showing a 234% increase in luminescence as compared to DHT alone 
(Fig. S4). 
Estrogenic activity was observed for 6 compounds: p,p’- 
Table 5 
Analytical Anti-Androgenic Equivalents (Anti-AR-EQs) of individual chemicals based on GC-HRMS analysis of the nonpolar fractions of the full-term amniotic fluid 
(AF), expressed in ng flutamide equivalents/L AF (ng Flu-EQs/L).    
Analytical Anti-Androgenic EQs (ng Flu-EQs/L) 
∑
Anti-AR-EQs per compound % Contribution to 
∑
Analytical Anti-AR-EQs  
REPs* F17 F18 F19 F20 F21 F22 F23 
Flutamide  1.00 – –  –  –  –  – –  – – 
BDE 3  0.01 – –  –  –  1.1  0.2 –  1.3 <1 
BDE 28  0.41 1.4 0.6  0.5  10.8  –  – –  13.3 2 
BDE 47  1.29 – –  –  –  0.8  0.5 –  1.3 <1 
BDE 99  0.17 – –  –  –  –  0.2 –  0.2 <1 
BDE 100  13.40 – –  –  201.8  –  – –  201.8 30 
BDE 153  0.10 0.7 2 × 10− 2  –  –  –  – –  0.7 <1 
BDE 183  0.10 – –  –  0.2  –  – –  0.2 <1 
6-OH-BDE 47  0.46 – –  6.3  –  –  – –  6.3 1 
p,p’-DDT  0.20 0.2 –  –  –  –  – –  0.2 <1 
o,p’-DDT  0.15 – –  0.3  0.6  0.2  0.1 –  1.2 <1 
p,p’-DDD  0.26 9.7 11.5  15.6  29.0  5.3  0.4 –  71.4 11 
o,p’-DDD  0.60 19.2 24.9  127.1  119.1  19.9  12.2 –  322.3 48 
Endrin  0.02 – –  –  –  0.2  0.7 –  0.9 <1 
Fonofos  0.02 3 × 10− 2 –  –  –  –  – –  <0.1 <1 
Heptachlor  0.01 – –  –  –  –  – –  – <1 
Lindane  0.07 – –  –  –  –  0.2 –  0.2 <1 
δ-Lindane  0.01 2.0 1.1  1.3  0.5  –  – –  5.0 1 
Triclosan  0.17 4.4 3.4  –  –  –  – –  7.8 1 
TPP  0.01 – –  –  –  0.3  – –  0.3 <1 
Pyrene  0.02 0.1 4 × 10− 2  –  0.1  –  – –  0.2 <1 
B[a]P  0.56 – 1.3  1.1  3.6  25.6  7.4 –  38.9 6 
∑Anti-AR EQs   37.6 42.8  152.1  365.7  53.4  21.7 –  673.3 100 
Note: *, relative potency (REP) values were retrieved from the literature as indicated in Table 2 and Supplementary Material Table S1. 
Table 6 
Anti-Androgenic Equivalents (Anti-AR-EQs) based on reporter gene activity (bioassay Anti-AR-EQs) and GC-HRMS analysis (analytical Anti-AR-EQs) of the nonpolar 
fractions of full-term amniotic fluid (AF), expressed in ng flutamide equivalents/L AF (ng Flu-EQs/L).  
Fraction number Bioassay Anti-AR-EQs (ng Flu-EQs/L)* Analytical Anti-AR-EQs (ng Flu-EQs/L) Explained (%) 
F17 6.9 × 104  37.6 <1 
F18 9.4 × 104  42.8 <1 
F19 5.4 × 104  152.2 <1 
F20 7.5 × 104  365.7 1 
F21 2.5 × 104  53.4 <1 
F22 1.9 × 104  21.8 <1 
F23 –  – ND 
∑
33.6 £ 104  673.3 <1 
Note: *, antagonistic activity of AF fractions was measured with co-exposure to 150 nM of DHT (positive control) in AR-Luc reporter gene assay, as described in the 
method section. 
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ditolylamine, benzoin isobutyl ether, diphenyl isophthalate, cholesterol 
n-propionate, BFBT, and CAB, of which diphenyl isophthalate and 
cholesterol n-propionate were the most potent, with EC50 of 8.2 × 10− 7 
M and 3.9 × 10− 7 M, respectively (Table 9). The REP of the tested 
candidates ranged from 10− 5 to 10− 6 of the potency of E2. Here, 
diphenyl isophthalate showed maximum agonistic activity of 163% as 
compared to the highest activity observed for the positive control E2, 
and a 217% increase in luminescence activity when co-exposed with E2 
(Table 9, Fig. S4). None of the tested compounds showed ER antagonistic 
activity. Additionally, two compounds (i.e., tridecyl benzoate and TTCP) 
were partial AhR agonists, showing weak dioxin-like activity. For these 
compounds only EC20 values could be derived (Table 9). The presence 
of 9 out of 14 candidates in AF fractions was confirmed with GC-HRMS 
and high-purity standards by comparing their exact masses, mass 
spectra and retention times to the data obtained during the non-targeted 
analysis (Table 9). 
4. Discussion 
Prenatal exposure to nonpolar EDCs is still largely unexplored, with 
the majority of research restricted to the analysis of well-known priority 
pollutants in maternal matrices, which are used as surrogates for the 
fetal environment (Barr et al., 2005). This study is the first to investigate 
a wide range of known and novel nonpolar EDCs in AF, an in utero matrix 
representative of direct fetal exposure. Previously, using an effect- 
directed analysis (EDA) approach, we discovered significant (anti-)es-
trogenic, (anti-)androgenic and dioxin-like activity in nonpolar fractions 
of full-term AF which could not be attributed to the presence of natural 
endogenous hormones (Dusza et al., 2019). The discovery of endocrine 
activity in nonpolar fractions was noteworthy given the aqueous nature 
of AF and the very low concentrations generally reported for nonpolar 
compounds in this matrix. In this study, through targeted and non- 
targeted GC-HRMS analysis and an innovative weight of evidence 
approach, we identified known and novel EDCs that, at least partially, 
were responsible for the observed endocrine activity. 
Table 7 
Analytical Estrogenic Equivalents (EEQs) of individual chemicals based on GC-HRMS analysis of the nonpolar fractions of the full-term amniotic fluid (AF), expressed 
in ng estradiol equivalents/L AF (ng E2-EQs/L).    








REP F17 F18 F19 F20 F21 F22 F23 
E2 1.0 – – – – – – – – – 
BDE 28 3 ×
10− 7 
9 × 10− 7 4 × 10− 7 3 × 10− 7 7 × 10− 6 – – – 9 × 10− 6 2 
BDE 47 3 ×
10− 7 
– – – – 2 × 10− 7 1 × 10− 7 – 3 × 10− 7 <1 
BDE 100 6 ×
10− 7 
– – – 9 × 10− 6 – – – 9 × 10− 6 2 
p,p’-DDT 6 ×
10− 7 
5 × 10− 7 – – – – – – 5 × 10− 7 <1 
o,p’-DDT 2 ×
10− 6 
– – 3 × 10− 6 6 × 10− 6 2 × 10− 6 1 × 10− 6 – 1 × 10− 5 3 
p,p’-DDD 1 ×
10− 7 
4 × 10− 6 5 × 10− 6 6 × 10− 6 1 × 10− 5 2 × 10− 6 2 × 10− 7 – 3 × 10− 5 7 
o,p’-DDD 5 ×
10− 7 
2 × 10− 5 2 × 10− 5 1 × 10− 4 1 × 10− 4 2 × 10− 5 2 × 10− 6 – 3 × 10− 4 59 
Endrin 1 ×
10− 7 
– – – – 2 × 10− 6 5 × 10− 6 – 7 × 10− 6 2 
β-HCH 1 ×
10− 6 
8 × 10− 7 1 × 10− 6 2 × 10− 6 1 × 10− 6 2 × 10− 6 2 × 10− 6 – 9 × 10− 6 2 
Triclosan 2 ×
10− 6 
4 × 10− 5 3 × 10− 5 – – – – – 7 × 10− 5 15 
TPP 4 ×
10− 7 
– – – – 2 × 10− 5 – – 2 × 10− 5 4 
Azobenzene 6 ×
10− 8 
2 × 10− 6 – 3 × 10− 6 8 × 10− 6 2 × 10− 6 8 × 10− 7 1 × 10− 7 2 × 10− 5 4 
B[a]P 9 ×
10− 8 
– 2 × 10− 7 2 × 10− 7 6 × 10− 7 4 × 10− 6 1 × 10− 6 – 6 × 10− 6 1 
B[b]F 7 ×
10− 8 
4 × 10− 8 5 × 10− 9 5 × 10− 9 7 × 10− 9 2 × 10− 8 3 × 10− 8 2 × 10− 7 3 × 10− 7 <1 














4 £ 10− 4 100 
Note: *, relative potency (REP) values were retrieved from the literature as indicated in Table 2 and Supplementary Material Table S1. 
Table 8 
Estrogenic Equivalents (EEQs) based on reporter gene activity (bioassay EEQs) and GC-HRMS analysis (analytical EEQs) of the nonpolar fractions of full-term amniotic 
fluid (AF) expressed in ng estradiol equivalents/L AF (ng E2-EQs/L).  
Fraction number Bioassay EEQs (ng E2-EQ/L)* Analytical EEQs (ng E2-EQ/L) Explained (%) 
F17  0.3 6 × 10− 5 <1 
F18  0.2 6 × 10− 5 <1 
F19  – 1 × 10− 4 – 
F20  0.2 1 × 10− 4 <1 
F21  0.4 5 × 10− 5 <1 
F22  0.1 2 × 10− 5 <1 
F23  0.7 3 × 10− 7 <1 
∑
1.8 4 £ 10− 4 <1 
Note: *, agonistic activity of AF fractions was measured with ER-Luc reporter gene assay as described in the method section. 
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Table 9 
The IC20/IC50 (antagonism) or EC20/EC50 (agonism) of the candidate compounds confirmed in AR-Luc, ER-Luc and DR-GFP reporter gene assays. The maximum 
activity (MAX) was calculated as % of the highest activity observed in the concentration–response curve of the positive control flutamide, E2 and TCDD, respectively.   
AR-antagonism ER-agonism DR-agonism 
Compound (fraction nr.) IC20 (M) IC50 (M) MAX (%) EC20 (M) EC50 (M) MAX (%) EC20 (M) EC50 (M) MAX (%) 
E2 ND ND ND 1.0 × 10− 12 3.0 × 10− 12 100 ND ND ND 
Flutamide 1.4 × 10− 7 1.0 × 10− 6 100 ND ND ND ND ND ND 
TCDD (F23) – – – ND ND ND 4.8 × 10− 12 11.4 × 10− 12 100 
Allethrin (F20) 3.0 × 10− 6 7.7 × 10− 6 100 – – – – – – 
Methyl oleate (F23) – – – – – – – – – 
Tridecyl benzoate (F22) – – – – – – 3.0 × 10− 5 – 42 
p,p’-Ditolylamine (F19) 2.4 × 10− 5 3.7 × 10− 5 95 1.6 × 10− 6 4.7 × 10− 6 78 – – – 
Benzoin isobutyl ether (F23) 3.1 × 10− 5 3.4 × 10− 5 100 1.1 × 10− 6 – 33 – – – 
Diphenyl isophthalate (F22) – – – 6.9 × 10− 7 8.2 × 10− 7 163 – – – 
Cholesterol n-propionate (F23) 1.1 × 10− 5 1.9 × 10− 5 100 2.4 × 10− 7 3.9 × 10− 7 95 – – – 
BTT (F21) 7.6 × 10− 6 1.4 × 10− 5 100 – – – – – – 
NABD (F20) 3.4 × 10− 6 6.9 × 10− 6 100 – – – – – – 
BNPa (F22) – – – – – – – – – 
BFBTa (F21) 1.0 × 10− 5 3.1 × 10− 5 72 1.3 × 10− 6 2.2 × 10− 6 113 – – – 
TTCPa (F18) – – – – – – 1.8 × 10− 5 – 46 
BMDa (F21) 3.3 × 10− 6 5.2 × 10− 6 100 – – – – – – 
CABa (F20) 5.9 × 10− 6 1.4 × 10− 5 100 2.2 × 10− 6 9.7 × 10− 6 57 – – – 
Note: Abbrev.: BTT, 6-Benzyl-3-(thiophen-3-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole; NABD, N,N’-Di-acridin-9-yl-benzene-1,4-diamine; BNP, 4,6-Bis(4-ethoxy-
benzylthio)-5-nitropyrimidine; BFBT, 1H-Benzoimidazole, 1-(4-fluorobenzyl)-2-p-tolyloxymethyl-; TTCP, [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole, 3-(4-chlor-
ophenyl)-6-(4-pyridinyl)-; BMD, 1H-Benzimidazole, 1,2-diphenyl-; CAB, Cyclohexanone, 2-(α-anilinobenzyl)-; ND, not determined; NA, not applicable; -, not active; a, 
compounds not confirmed chemically. 
Fig. 3. Estrogenic (A) and anti-androgenic (B) activity of novel identified compounds in AF fractions, measured in ER-Luc and AR-Luc reporter gene assay, 
respectively. In the ER-Luc assay, the % response is expressed relative to the maximum induction by 50 pM E2. In the AR-Luc assay, cells were co-exposed with DHT 
and the antagonistic response is expressed relative to 150 pM DHT, n = 3. 
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4.1. Known and novel nonpolar EDCs in AF 
The targeted analysis of nonpolar AF fractions revealed a wide range 
of nonpolar EDCs from multiple chemical classes, many of which never 
before measured in AF samples (Table 1). The presence of these com-
pounds in AF undoubtedly demonstrates placental transfer and fetal 
exposure. Many of the 42 compounds detected, such as organochlorine 
pesticides (OCPs), PCBs and dioxin and furans, are known as persistent 
organic pollutants (POPs), recognized for their high toxicity, slow 
degradation, bioaccumulation and long biological half-lives. Although 
the production and use of these POPs have been banned or severely 
restricted (The Stockholm Convention on Persistent Organic Pollutants, 
2001), they are continuously and frequently detected in maternal and 
fetal tissues and thus their legacy persists (Al-Saleh et al., 2012; Barmpas 
et al., 2020; Jaraczewska et al., 2006; Luzardo et al., 2009). 
Three OCPs namely, o,p’-DDD, p,p’-DDD and δ-HCH, were the most 
abundant compounds detected in AF during the targeted analysis. DDT 
is omnipresent in the environment and is usually detected in >90% of 
samples including maternal matrices (Jayaraj et al., 2016; Peng et al., 
2021; Sharma et al., 2014). Typically, DDE is the most abundant 
metabolite of DDT measured in maternal serum, placenta or cord blood 
(Barmpas et al., 2020; Shen et al., 2007; Zhao et al., 2007). Considering 
that AF is largely a product of fetal metabolic activity, the higher con-
centrations of o,p’-DDD and p,p’-DDD detected in AF could be indicative 
of specific in utero metabolism and/or toxicokinetics. The reports on the 
presence of these compounds in AF are limited, however, one recent 
study corroborated our findings i.e., p,p’-DDD was measured in AF but 
not in maternal serum (Barmpas et al., 2020). Other OCPs, such as 
heptachlor and endrin, were also detected but were present at much 
lower levels (Table 1). 
Although Penta- and Octa-BDEs have been largely phased out, Deca- 
BDE is still produced and used (Alaee et al., 2003). The presence of these 
compounds in maternal blood, cord blood and placenta, has been pre-
viously demonstrated (Frederiksen et al., 2009; Mazdai et al., 2003; 
Vizcaino et al., 2014). It has been suggested that the higher relative 
bromination of BDEs may decrease transplacental transport due to 
increased molecular weight, resulting in a higher concentration found in 
e.g., maternal blood rather than cord blood (Aylward et al., 2014; 
Frederiksen et al., 2010). In this study, Penta-, Octa-, Deca-BDE and 
higher brominated BDEs (e.g., BDE 209) were detected in AF above 
LODs, with the latter detected at a higher concentration than some of the 
more common lower brominated BDEs, such as DBE 47. This suggests 
that despite the high bromination, BDE 209 pass effectively through the 
placenta barrier. It is possible that the higher brominated compounds 
accumulate in utero e.g., due to low placental and fetal clearance, 
however, this is still largely unexplored (Alcorn and McNamara, 2003; 
Vizcaino et al., 2014). To our knowledge, only one other study measured 
BDEs in AF, and the congeners and concentrations reported were similar 
to the ones reported here (Miller et al., 2012). 
Only 5 out of 14 PCB congeners analysed were detected above LODs 
(Table 1). The low concentration range measured in this study (low ng/L 
range) fell within the concentration range reported in AF by other au-
thors (Barmpas et al., 2020; Daglioglu et al., 2013; Foster et al., 2000; 
Luzardo et al., 2009; van der Ven et al., 1992) and in general, was much 
lower than that reported in maternal serum (Jaraczewska et al., 2006; 
Park et al., 2008). The presence of the higher chlorinated PCBs in our 
samples (e.g., PCB 206, 138), corroborated by few other studies (Correia 
Carreira et al., 2011; Luzardo et al., 2009; van der Ven et al., 1992; 
Vizcaino et al., 2014), confirms their bioavailability and transplacental 
transport. 
PAHs such as IPyr, B[a]P and B[b]F were detected in this study, as 
well as a small number of other studies that analysed human AF 
(Machado et al., 2014; Myers et al., 2008, 2003). Maternal exposure to 
PAHs and their ability to cross the placenta and reach cord blood has 
already been demonstrated (Gladen et al., 2000; Singh et al., 2008; 
Zhang et al., 2017). However, to our knowledge, this study is the first to 
detect the most potent, highly toxic dioxins i.e., 2,3,7,8-TCDD, 1,2,3,7,8- 
PCDD and 1,2,3,4,7,8-HCDF in human AF samples (Tables 1 & 2). 
Although the past decades have seen a steady decrease in exposure to 
these compounds in the general population (Aylward and Hays, 2002), 
considering their high toxic potency (EC50 within pM range), the con-
centration measured here might be of toxicological significance. Taken 
together, maternal exposure to the chemicals detected in AF including 
dioxin and furans, OCPs, BDEs and PCBs have been linked, amongst 
other things, with impaired fetal neurodevelopment, metabolism and 
growth, changes in steroid hormone levels and increased prevalence of 
hormone-sensitive cancers, raising further concern for their contribution 
to the fetal origins of adult disease (Araki et al., 2018; Berghuis et al., 
2015; Bhatia et al., 2005; Burns et al., 2013; Herbstman et al., 2010; 
Mocarelli et al., 2008). 
Approximately 30% of the dioxin-like activity (Table 4) and only a 
small fraction of the estrogenic and (anti-)androgenic activity observed 
in the nonpolar fractions could be explained by the compounds dis-
cussed above (Tables 6 & 8), indicating the presence of potential novel, 
potent EDCs in the AF. Following our non-targeted suspect screening 
workflow, 121 unique compounds were tentatively identified in AF 
(Supplementary Excel File) including such diverse compounds as hexyl 
pivalate and octyl benzoate (fragrance agents), octyl methacrylate (ad-
hesive and components of coatings), neryl isovalerate (flavouring agent) 
and betamethadol (synthetic opioid analgesic). Squalene and heptade-
cane were the only two identified endogenous metabolites. This could be 
explained by the fact that the majority of endogenous compounds in the 
human body (e.g., hormones, fatty acids, amino acids, carbohydrates, 
cyclic amines) are polar or semi-polar (Psychogios et al., 2011) and 
therefore would not elute in the non-polar fractions analysed in this 
study. Only 8 out of the 121 Identified Unknowns were previously 
experimentally tested for their endocrine activity (Table S5). Further 
evaluation of their endocrine activity using in silico prediction and 
profiling tools resulted in a total of 69 additional suspects (Supple-
mentary Excel File). To our knowledge, none of these compounds were 
previously measured in AF samples, and for only a few of them, limited 
information on production and use was found. In a recent study, Wang 
et al. (2021) performed non-targeted screening of paired maternal and 
cord serum samples and tentatively identified 55 compounds previously 
not reported in human samples. There was no overlap between the 
compounds identified by Wang et al. (2021) and in this study, which is 
not surprising considering that Wang et al. (2021) focused mainly on 
polar industrial chemicals. Collectively, these studies show that there is 
a vast knowledge gap regarding in utero exposure to both polar and 
nonpolar environmental pollutants that calls for further investigation 
into their origins and possible health effects (Wang et al., 2021). 
From the 69 compounds with potential endocrine activity, 14 were 
chosen for further evaluation, based on the toxicity profile and com-
mercial availability (Table 9, Supplementary Excel File). From the six 
compounds confirmed to have estrogenic activity, diphenyl iso-
phthalate, a plasticizer and a flame retardant, was one of the most 
active, showing 10− 5 of the potency of E2. Interestingly, diphenyl iso-
phthalate showed supramaximal responses (i.e., induction of lumines-
cence at higher levels than the positive control E2), as well as, high 
androgenic activity in AR-Luc assay, but only after co-exposure to pos-
itive control DHT (Fig. S4). The mechanism behind the supramaximal 
responses is still not fully understood. The unexplained androgenic ac-
tivity observed in AF fractions may at least in part, stem from its mixture 
activity, which is typically overlooked when using REP values of indi-
vidual compounds. The information about diphenyl isophthalate in the 
literature is scarce and to our knowledge, this is the first report on its 
presence in human samples. The other potent ER agonists measured in 
AF were cholesterol n-propionate and p,p’-ditolylamine. The chemical 
structure of cholesterol n-propionate closely resembles estradiol, 
whereas p,p’-ditolylamine (an amine bound to two phenyl groups) re-
sembles the known endocrine disruptor bisphenol A (BPA), which may 
explain their estrogenic activity. Both compounds also acted as weak 
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anti-androgens (Table 9). The information about this compound in the 
literature is scarce, however, some online sources report them as in-
dustrial chemicals used mainly in semiconductors (www.tcichemicals. 
com). Similarly, benzoin isobutyl ether showed both ER and anti-AR 
activity (Table 9). Online sources report that it is used mainly as a 
coating auxiliary agent (www.mainchem.com). For the other active 
compounds confirmed in AF, limited to no information about their 
source or use could be found. 
4.2. Strengths and limitations in this study 
We developed a robust method for the analysis and identification of 
novel nonpolar EDCs in AF. The use of AF indisputably demonstrates 
placental transfer and fetal exposure and in general, might be a better 
approximation of fetal body burden to environmental pollutants than 
maternal matrices. Additionally, the wide range of nonpolar compounds 
detected in this study demonstrates that AF can be successfully used for 
the analysis of even highly lipophilic compounds. It should be noted that 
this study used a small number of AF samples, and larger epidemio-
logical investigations are needed to better understand the extent of 
exposure to these compounds in the general population. 
The analytical methods applied in this study, i.e. GC-HRMS is the 
method of choice for non-targeted screening of nonpolar compounds, 
which usually remain undetected with softer ionization methods like 
electron spray ionization (ESI) (Hollender et al., 2017). It provides trace 
level detection of highly nonpolar compounds (BDE 209, logP 9.97, 
Table 1), and allows for non-targeted detection of thousands of volatile 
substances. Matching spectral information with the compound’s reten-
tion time provides much improved tentative identifications (Hollender 
et al., 2017). In addition, LogP values increase the accuracy of chro-
matographic retention time prediction, narrowing the number of can-
didates that could elute in the nonpolar fraction during the 
chromatographic fractionation (Dusza et al., 2019). The two logP pre-
diction tools used in this study, Kowwin and OPERA, showed a high 
correlation between experimental and predicted logP values for the 
compounds detected during targeted analysis (Fig. S2). Nevertheless, 
discrepancies were found for approximately 20% of the Identified Un-
knowns. Cross-checking the inconsistencies with external databases (e. 
g., PubChem) greatly improved the compound selection process. 
The use of curated and freely available resources such as the 
CompTox Chemicals Dashboard, which contain a wealth of information 
for thousands of chemicals improved the identification and prioritiza-
tion of suspected EDCs from the list of tentatively identified compounds 
(McEachran et al., 2017; Williams et al., 2017). The ongoing advances in 
in vitro technologies, and increase in the availability of HTS data, 
continuously improve modelling algorithms and predictive perfor-
mances of QSAR in silico models. The reported sensitivity, specificity and 
accuracy of all QSARs used in this study were high (>80%, Table S4) and 
our data (i.e., the confirmed activity of 12 out of 14 suspected EDCs) 
validated the applicability of QSAR models for profiling of novel EDCs. 
Accordingly, there is a high degree of confidence that the list of 
remaining suspected EDCs that could not be tested in this study (Sup-
plementary Excel File) contains biologically active compounds that 
could contribute to the remaining, unexplained activity observed in the 
AF fractions. 
Regarding potential methodological limitations in this study, lipid 
adjustment is noteworthy. The low concentration range of nonpolar 
compounds reported in AF, including this study, may be attributed to the 
low concentration of lipids present in the full-term AF (Singh and 
Zuspan, 1973). Lipid adjustment is a common practice in order to 
compare the inter and intra-individual differences in lipophilic toxicant 
concentration (Bernert et al., 2007; O’Brien et al., 2017); however, it is 
not without pitfalls. For highly lipophilic, nonpolar compounds, tissue 
distributions are more closely related to the lipid composition, rather 
than total lipids (Elskus et al., 2005; Kammann et al., 1990). The AF lipid 
profile is highly specific and differs significantly from the maternal 
plasma (Biezenski et al., 1968). The differences in ratio and composition 
of polar (e.g., phospholipids) to neutral lipids (e.g., cholesterol, tri-
glycerides) in AF and maternal plasma might therefore influence 
nonpolar EDC distribution, however, this is still largely unexplored. 
Moreover, a mixture of developmental waste products and small organic 
constituents (cells, nutrients, growth factors and proteins) present in AF 
provide additional matter to which nonpolar compounds may sequester 
(Underwood et al., 2005). In particular, as binding to plasma protein is a 
competitive process between exogenous compounds and endogenous 
ligands, specifically free fatty acids (Syme et al., 2004), lower fatty acids 
concentration in AF as compared to maternal serum might increase EDC 
binding to proteins and other organic matter present in AF. This illus-
trates that measurements adjusted for lipid content may not yield 
meaningful values. Consequently, extrapolation of AF concentration to 
maternal matrices, based on lipid adjustment, is challenging and should 
be performed with caution. 
Additional methodological limitations may lie in the bioassays used 
to measure endocrine activity, or in the EDA approach. Although dioxin- 
like activity in AF fractions could be partially attributed to the analytical 
TEQ measured, the observed ER and AR activity was largely unexplained 
by their respective analytical EQs (Tables 6 & 8). It is possible that the 
unexplained (anti-)androgenic activity, to some degree, stems from the 
use of MDA-kb2 cells which stably express an androgen-responsive 
luciferase reporter gene construct that responds to compounds that 
activate not only the AR but also the glucocorticoid receptor (GR) 
(Wilson et al., 2002). Thus, the contribution of GR active compounds to 
the observed androgen activity cannot be excluded. Furthermore, in our 
EDA approach, though chromatographic separation ensures the reduc-
tion of the chemical complexity of the sample, there could be masking 
effects of co-eluting agonists and antagonists (Weiss et al., 2009), or 
unknown mixture effects resulting in significantly lower or higher 
bioassay activity than calculated based on the individual REP values 
(Orton et al., 2014), as shown with diphenyl isophthalate (Fig. S4). 
Higher-resolution fractionation may further decrease chemical 
complexity, but at the same time could result in lower bioassay sensi-
tivity due to compounds being split over multiple fractions. Such trade- 
offs are inherent to the EDA approach, especially when measured 
compounds are expected to be present at low levels. 
5. Conclusions 
While several thousand man-made substances have been detected to 
date in the environment, the number of compounds with endocrine- 
disrupting properties that the fetus might be exposed to is still largely 
unknown. The workflow used in this study i.e., the combination of tar-
geted and non-targeted GC-HRMS analysis of AF together with the 
application of curated and freely available in vitro experimental data and 
in silico prediction tools, provided a powerful tool to identify known and 
novel nonpolar EDCs in the fetal environment. Although we measured a 
wide variety of known EDCs in AF the remaining, largely unexplained 
endocrine activity observed in the nonpolar fractions indicates the 
presence of potential, novel active compounds. The non-targeted anal-
ysis together with the innovative, weight of evidence data mining 
approach, allowed for the identification of additional suspected EDCs, 
for which limited to no information on their production and use was 
found. This study contributes to a better understanding of the fetal 
exposome and shows that the fetus may be directly exposed to many 
more EDCs than previously thought, including novel unknown com-
pounds. Further research is needed to better understand the source, 
nature and extent of exposure to these compounds and their possible 
effects on fetal development and long-term health. 
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Alaee, M., Arias, P., Sjödin, A., Bergman, Å., 2003. An overview of commercially used 
brominated flame retardants, their applications, their use patterns in different 
countries/regions and possible modes of release. Environ. Int. 29, 683–689. https:// 
doi.org/10.1016/S0160-4120(03)00121-1. 
Alcorn, J., McNamara, P.J., 2003. Pharmacokinetics in the newborn. Adv. Drug Deliv. 
Rev. 55, 667–686. https://doi.org/10.1016/S0169-409X(03)00030-9. 
Andersson, A.-M., Bay, K., Frederiksen, H., Skakkebæk, N.E., 2016. Endocrine disrupters: 
we need research, biomonitoring and action. Andrology 4, 556–560. https://doi. 
org/10.1111/ANDR.12244. 
Araki, A., Miyashita, C., Mitsui, T., Goudarzi, H., Mizutani, F., Chisaki, Y., et al., 2018. 
Prenatal organochlorine pesticide exposure and the disruption of steroids and 
reproductive hormones in cord blood: The Hokkaido study. Environ. Int. 110, 1–13. 
https://doi.org/10.1016/j.envint.2017.10.006. 
Aylward, L.L., Hays, S.M., 2002. Temporal trends in human TCDD body burden: 
Decreases over three decades and implications for exposure levels. J. Expo. Anal. 
Environ. Epidemiol. 12, 319–328. https://doi.org/10.1038/sj.jea.7500233. 
Aylward, L.L., Hays, S.M., Kirman, C.R., Marchitti, S.A., Kenneke, J.F., English, C., et al., 
2014. Relationships of chemical concentrations in maternal and cord blood: a review 
of available data. J. Toxicol. Environ. Health B Crit. Rev. 17, 175–203. https://doi. 
org/10.1080/10937404.2014.884956. 
Barmpas, M., Vakonaki, E., Tzatzarakis, M., Sifakis, S., Alegakis, A., Grigoriadis, T., et al., 
2020. Organochlorine pollutants’ levels in hair, amniotic fluid and serum samples of 
pregnant women in Greece. A cohort study. Environ. Toxicol. Pharmacol. 73, 
103279. https://doi.org/10.1016/j.etap.2019.103279. 
Barr, D.B., Wang, R.Y., Needham, L.L., Barr, D.B., Wang, R.Y., Needham, L.L., 2005. 
Biologic Monitoring of Exposure to Environmental Chemicals throughout the Life 
Stages : Requirements and Issues for Consideration for the National Children ’ s 
Study. Environ. Health Perspect. 113, 1083–1091. https://doi.org/10.1289/ 
ehp.76l7. 
Bellanger, M., Demeneix, B., Grandjean, P., Zoeller, R.T., Trasande, L., 2015. 
Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine- 
disrupting chemicals in the European Union. J. Clin. Endocrinol. Metab. 100, 
1256–1266. https://doi.org/10.1210/jc.2014-4323. 
Berghuis, S.A., Bos, A.F., Sauer, P.J.J., Roze, E., 2015. Developmental neurotoxicity of 
persistent organic pollutants: an update on childhood outcome. Arch. Toxicol. 89, 
687–709. https://doi.org/10.1007/s00204-015-1463-3. 
Bernert, J.T., Turner, W.E., Patterson, D.G., Needham, L.L., 2007. Calculation of serum 
“total lipid” concentrations for the adjustment of persistent organohalogen toxicant 
measurements in human samples. Chemosphere 68, 824–831. https://doi.org/ 
10.1016/j.chemosphere.2007.02.043. 
Bhatia, R., Shiau, R., Petreas, M., Weintraub, J.M., Farhang, L., Eskenazi, B., 2005. 
Organochlorine pesticides and male genital anomalies in the child health and 
development studies. Environ. Health Perspect. 113, 220–224. https://doi.org/ 
10.1289/ehp.7382. 
Biezenski, J.J., Pomerance, W., Goodman, J., 1968. Studies on the origin of amniotic 
fluid lipids. I. Normal composition. Am. J. Obstet. Gynecol. 102, 853–861. https:// 
doi.org/10.1016/0002-9378(68)90514-0. 
Bonefeld-Jørgensen, E.C., Ghisari, M., Wielsøe, M., Bjerregaard-Olesen, C., Kjeldsen, L.S., 
Long, M., 2014. Biomonitoring and hormone-disrupting effect biomarkers of 
persistent organic pollutants in vitro and ex vivo. Basic Clin. Pharmacol. Toxicol. 
115, 118–128. https://doi.org/10.1111/bcpt.12263. 
Bradman, A., Barr, D.B., Henn, B.G.C., Drumheller, T., Curry, C., Eskenazi, B., 2003. 
Measurement of pesticides and other toxicants in amniotic fluid as a potential 
biomarker of prenatal exposure: A validation study. Environ. Health Perspect. 111, 
1779–1782. https://doi.org/10.1289/ehp.6259. 
Braekevelt, E., Tittlemier, S., Tomy, G., 2003. Direct measurement of octanol–water 
partition coefficients of some environmentally relevant brominated diphenyl ether 
congeners. Chemosphere 51 (7), 563–567. https://doi.org/10.1016/S0045-6535 
(02)00841-X. 
Burns, C.J., McIntosh, L.J., Mink, P.J., Jurek, A.M., Li, A.A., 2013. Pesticide exposure and 
neurodevelopmental outcomes: Review of the epidemiologic and animal studies. J . 
Toxicol. Environ. Heal. - Part B Crit. Rev. 16, 127–283. https://doi.org/10.1080/ 
10937404.2013.783383. 
Burt, L., Blair, J., Dropps, K., 2012. Prenatal alcohol exposure, blood alcohol 
concentrations and alcohol elimination rates for the mother, fetus and newborn. 
J. Perinatol. 32, 652–659. https://doi.org/10.1038/jp.2012.57. 
Cooke, G.M., 2014. Biomonitoring of human fetal exposure to environmental chemicals 
in early pregnancy. J. Toxicol. Environ. Heal - Part B Crit. Rev. 17, 205–224. https:// 
doi.org/10.1080/10937404.2014.898167. 
Correia Carreira, S., Cartwright, L., Mathiesen, L., Knudsen, L.E., Saunders, M., 2011. 
Studying placental transfer of highly purified non-dioxin-like PCBs in two models of 
the placental barrier. Placenta 32, 283–291. https://doi.org/10.1016/j. 
placenta.2010.12.024. 
Daglioglu, N., Akcan, R., Efeoglu, P., Inandiklioglu, N., Korkut Gulmen, M., 
Demirhan, O., 2013. Polychlorinated biphenyls and organochlorine pesticides in 
amniotic fluids of pregnant women in south-central Turkey †. Toxicol. Environ. 
Chem. 95, 954–961. https://doi.org/10.1080/02772248.2013.840370. 
Danish (Q)SAR Database, Division of Diet, Disease Prevention and Toxicology N, Food 
Institute, Technical University of Denmark H food. dtu. dk. 2015. Danish (Q)SAR 
Database. Available: http://qsar.food.dtu.dk/ [accessed 20 October 2019]. 
Deji, Z., Liu, P., Wang, X., Zhang, X., Luo, Y., Huang, Z., 2021. Association between 
maternal exposure to perfluoroalkyl and polyfluoroalkyl substances and risks of 
adverse pregnancy outcomes: A systematic review and meta-analysis. Sci. Total 
Environ. 783 https://doi.org/10.1016/j.scitotenv.2021.146984. 
Dusza, H., Janssen, E., Kanda, R., Legler, J., 2019. Method development for effect- 
directed analysis of endocrine disrupting compounds in human amniotic fluid. acs. 
est.9b04255 Environ. Sci. Technol.. https://doi.org/10.1021/acs.est.9b04255. 
Elskus, A.A., Collier, T.K., Monosson, E., 2005. Chapter 4 Interactions between lipids and 
persistent organic pollutants in fish. Biochem. Mol. Biol. Fishes 6, 119–152. https:// 
doi.org/10.1016/S1873-0140(05)80007-4. 
Foster, W., Chan, S., Platt, L., Hughes, C., 2000. Detection of endocrine disrupting 
chemicals in samples of second trimester human amniotic fluid. J. Clin. Endocrinol. 
Metab. 85, 2954–2957. 
Frederiksen, M., Thomsen, C., Frøshaug, M., Vorkamp, K., Thomsen, M., Becher, G., 
et al., 2010. Polybrominated diphenyl ethers in paired samples of maternal and 
umbilical cord blood plasma and associations with house dust in a Danish cohort. 
Int. J. Hyg. Environ. Health 213, 233–242. https://doi.org/10.1016/j. 
ijheh.2010.04.008. 
Frederiksen, M., Thomsen, M., Vorkamp, K., Knudsen, L.E., 2009. Patterns and 
concentration levels of polybrominated diphenyl ethers (PBDEs) in placental tissue 
of women in Denmark. Chemosphere 76, 1464–1469. https://doi.org/10.1016/j. 
chemosphere.2009.07.017. 
Gladen, B.C., Zadorozhnaja, T.D., Chislovska, N., Hryhorczuk, D.O., Kennicutt, M.C., 
Little, R.E., 2000. Polycyclic aromatic hydrocarbons in placenta. Hum. Exp. Toxicol. 
19, 597–603. https://doi.org/10.1191/096032700671433928. 
Gore, A.C., Chappell, V.A., Fenton, S.E., Flaws, J.A., Nadal, A., Prins, G.S., et al., 2015. 
Executive Summary to EDC-2: The Endocrine Society ’ s Second Scientific Statement 
on Endocrine-disrupting Chemicals. Endocr. Rev. 36, 1–10. https://doi.org/ 
10.1210/er.2015-1093. 
Hamers, T., Kamstra, J.H., Cenijn, P.H., Pencikova, K., Palkova, L., Simeckova, P., et al., 
2011. In Vitro Toxicity Profiling of Ultrapure Non-Dioxin-like Polychlorinated 
Biphenyl Congeners and Their Relative Toxic Contribution to PCB Mixtures in 
Humans. Toxicol. Sci. 121, 88–100. https://doi.org/10.1093/toxsci/kfr043. 
Hamers, T., Kamstra, J., Sonneveld, E., Albertinka, J., Murk, J., 2006. In vitro profiling of 
the endocrine-disrupting potency of brominated flame retardants. Toxicol. Sci. 92 
(1), 157–173. 
Heindel, J.J., Balbus, J., Birnbaum, L., Brune-Drisse, M.N., Grandjean, P., Gray, K., et al., 
2015. Developmental origins of health and disease: Integrating environmental 
influences. Endocrinology 156, 3416–3421. https://doi.org/10.1210/EN.2015- 
1394. 
Heindel, J.J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M.A., 
et al., 2017. Metabolism disrupting chemicals and metabolic disorders. Reprod. 
Toxicol. 68, 3–33. https://doi.org/10.1016/j.reprotox.2016.10.001. 
Heindel, J.J., Vandenberg, L.N., 2015. Developmental origins of health and disease: a 
paradigm for understanding disease cause and prevention. Curr. Opin. Pediatr. 27, 
248–253. https://doi.org/10.1097/MOP.0000000000000191. 
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